MedTrace Logo

PreFER Managed Ventricular Pacing (MVP) For Elective Replacement

NCT00293241 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 630

Last updated 2016-06-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate the benefit of MVP in pacemaker and implantable cardioverter defibrillator (ICD) patients with a history of right ventricular pacing.

Conditions

Interventions

DEVICE

Managed Ventricular Pacing programmed ON/OFF

Device programming

Sponsors & Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

    lead INDUSTRY

Principal Investigators

  • Oliver Piot, Dr. · Centre Cardiologique du Nord, Saint-Denis, France

  • Aurelio Quesada, Dr. · Hospital General Universitario de Valencia, Spain

  • De Roy, Prof. · Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium

  • Renato Ricci, Dr. · San Filippo Neri Hospital, Rome, Italy

  • Gianluca Botto, Dr. · Como S. Anna Hospital, Como, Italy

  • Milan Kozak, Dr. · Fakultní nemocnice Brno Bohunice, Brno, Czech Republic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293241 on ClinicalTrials.gov